Outcomes
The impact on the progression of AR was measured by symptomatic AR medication prescription after expiry of AIT treatment considering the probability of requiring symptomatic AR medication in the follow-up period and the number and reduction of AR prescriptions in the follow-up period standardized by year compared to the pre-index period.
For asthmatic patients, defined as patients treated with two prescriptions of an anti-asthmatic medication in the same or two sub-sequent allergy seasons, the impact of the study products on the progression of asthma was measured analogously. The other patients were classified as non-asthmatic at baseline. After expiry of AIT treatment the impact of the study products on the progression of asthma was measured by the probability of requiring anti-asthmatic medication and number and reduction of anti-asthmatic prescriptions in the follow-up period standardized by year after AIT compared to the pre-index period.
For non-asthmatic patients at index date, the impact on asthma incidence was measured analogously by the occurrence and by time to prescription of anti-asthmatic medication in the follow-up period.